Krystal Biotech Inc reports results for the quarter ended in September - Earnings Summary

Krystal Biotech

07/11/2022 14:32

* Krystal Biotech Inc  KRYS.OQ  reported a quarterly
adjusted loss
of $1.17​​ per share for the quarter ended in September. The
mean expectation of seven analysts for the quarter was for a
loss of $1.22 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Krystal Biotech Inc's reported EPS for the quarter was a
loss of
$1.17​.
    * The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Krystal Biotech Inc shares had risen by 5.0% this
quarter and
gained 4.7% so far this year.
    * The company reported a quarterly loss of $29.85 million.
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $104.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.22          -1.17          Beat
 Jun. 30 2022      -1.02          -1.10          Missed
 Mar. 31 2022      -1.05          -0.99          Beat
 Dec. 31 2021      -0.73          -0.95          Missed